

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

## SAFETY DATA SHEET

A1000 GLOSS BASE SIGNAL GREY RAL 7004

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

| 1.1 Product ident | tifier |
|-------------------|--------|
|-------------------|--------|

Product name SDS code

: A1000 GLOSS BASE SIGNAL GREY RAL 7004 : 12907004B

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

|                       | Identified uses                           |  |
|-----------------------|---|--|
| Paint. Professional u | se Industrial use                         |  |
|                       | Uses advised against                      |  |
| All other uses        |   |  |
| Product use           | : Solvent borne coating for exterior use. |  |

#### 1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

#### 1.4 Emergency telephone number

| National advisory body/Poison Center |  |  |  |  |
|--------------------------------------|--|--|--|--|
| Telephone number                     | : +358 (0)9 471977                             |  |  |  |
| <u>Supplier</u>                      |  |  |  |  |
| Telephone number                     | : +33 (0)5 34 01 34 01<br>+33 (0)5 61 60 23 30 |  |  |  |
| Hours of operation                   | :  |  |  |  |

## SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Product definition** : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Sens. 1, H317 STOT SE 3, H336 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

| Date of issue/Date of revision | : 1-11-2022  | Version : 1.02 |           |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue         | : 21-10-2022 | 1/19           | AkzoNobel |

## **SECTION 2: Hazards identification**

| 2.2 Label elements  |  |    |
|---|--|----|
| Hazard pictograms   |  |    |
| Signal word   | : Warning  |    |
| Hazard statements   | : Flammable liquid and vapor.<br>May cause an allergic skin reaction.<br>May cause drowsiness or dizziness.<br>Harmful to aquatic life with long lasting effects.  |    |
| Precautionary statements  |  |    |
| Prevention  | : Wear protective gloves. Keep away from heat, hot surfaces, sparks, open flame<br>and other ignition sources. No smoking. Avoid release to the environment. Avo<br>breathing vapor.   |    |
| Response  | : IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty water. If skin irritation or rash occurs: Get medical advice or attention.                      | of |
| Storage   | : Store in a well-ventilated place. Keep container tightly closed. Keep cool.  |    |
| Disposal  | : Dispose of contents and container in accordance with all local, regional, national and international regulations.  | I  |
| Hazardous ingredients   | : 2-ethoxy-1-methylethyl acetate<br>n-butyl acetate<br>Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl<br>1,2,2,6,6-pentamethyl-4-piperidyl sebacate<br>Hydroxyphenyl-benzotriazole derivatives<br>Polymeric Benzotriazole |    |
| Supplemental label<br>elements  | : Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.   |    |
| Annex XVII - Restrictions<br>on the manufacture,<br>placing on the market and<br>use of certain dangerous<br>substances, mixtures and<br>articles | : Not applicable.  |    |
| Special packaging requirem  | ents   |    |
| Containers to be fitted<br>with child-resistant<br>fastenings   | : Not applicable.  |    |
| Tactile warning of danger   | : Not applicable.  |    |
| 2.3 Other hazards<br>Product meets the criteria<br>for PBT or vPvB according<br>to Regulation (EC) No.<br>1907/2006, Annex XIII                   | : This mixture does not contain any substances that are assessed to be a PBT or vPvB.  | а  |
| Other hazards which do not result in classification   | : None known.  |    |



## **SECTION 3: Composition/information on ingredients**

| 3.2 Mixtures : N  | /ixture   | 1         |  |         |
|---|---|-----------|--|---------|
| Product/ingredient name   | Identifiers   | %         | Regulation (EC) No.<br>1272/2008 [CLP]   | Туре    |
| -ethoxy-1-methylethyl acetate   | EC: 259-370-9<br>CAS: 54839-24-6<br>Index: 603-177-00-8                               | ≥10 - ≤25 | Flam. Liq. 3, H226<br>STOT SE 3, H336  | [1]     |
| n-butyl acetate   | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1 | ≥10 - ≤15 | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066  | [1] [2] |
| 2-methoxy-1-methylethyl acetate   | REACH #:<br>01-2119475791-29<br>EC: 203-603-9<br>CAS: 108-65-6                        | ≤5        | Flam. Liq. 3, H226<br>STOT SE 3, H336  | [1] [2] |
| Reaction mass of ethylbenzene<br>and xylene   | REACH #:<br>01-2119488216-32  | ≤3        | Flam. Liq. 3, H226<br>Acute Tox. 4, H312<br>Acute Tox. 4, H332<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT RE 2, H373<br>Asp. Tox. 1, H304<br>Aquatic Chronic 3,<br>H412 | [1] [2] |
| Reaction mass of Bis<br>(1,2,2,6,6-pentamethyl-4-piperidyl)<br>sebacate and Methyl<br>1,2,2,6,6-pentamethyl-4-piperidyl<br>sebacate | REACH #:<br>01-2119491304-40<br>EC: 915-687-0<br>CAS: 1065336-91-5                    | ≤1        | Skin Sens. 1A, H317<br>Repr. 2, H361f<br>Aquatic Acute 1, H400<br>(M=1)<br>Aquatic Chronic 1,<br>H410 (M=1)  | [1]     |
| Hydroxyphenyl-benzotriazole<br>derivatives  | REACH #:<br>01-0000015075-76<br>EC: 400-830-7<br>CAS: 104810-48-2                     | <1        | Skin Sens. 1, H317<br>Aquatic Chronic 2,<br>H411   | [1]     |
| 4-methylpentan-2-one  | EC: 203-550-1<br>CAS: 108-10-1<br>Index: 606-004-00-4                                 | ≤0.7      | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>Eye Irrit. 2, H319<br>Carc. 2, H351<br>STOT SE 3, H336<br>EUH066   | [1] [2] |
| Polymeric Benzotriazole   | CAS: 104810-47-1  | <1        | Skin Sens. 1, H317<br>Aquatic Chronic 2,<br>H411   | [1]     |
| Hydrocarbons, C10-C13, n-<br>alkanes, isoalkanes, cyclics, < 2%<br>aromatics  | REACH #:<br>01-2119457273-39<br>EC: 918-481-9   | ≤0.55     | Asp. Tox. 1, H304<br>EUH066  | [1]     |
| Hexanoic acid, 2-ethyl-, zinc salt, basic   | REACH #:<br>01-2119979093-30<br>EC: 286-272-3<br>CAS: 85203-81-2                      | ≤0.3      | Eye Irrit. 2, H319<br>Repr. 2, H361d (oral)<br>Aquatic Chronic 3,<br>H412  | [1]     |
| propylidynetrimethanol  | EC: 201-074-9<br>CAS: 77-99-6   | ≤0.3      | Repr. 2, H361  | [1]     |
|   |   |           | See Section 16 for<br>the full text of the H<br>statements declared<br>above.  |         |

| Date of issue/Date of revision | : 1-11-2022  | Version : 1.02 |           |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue         | : 21-10-2022 | 3/19           | AkzoNobel |

## **SECTION 3: Composition/information on ingredients**

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### Туре

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

## **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

| Eye contact                | : | Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.  |
|----------------------------|---|---|
| Inhalation                 | : | Remove victim to fresh air and keep at rest in a position comfortable for breathing.<br>If it is suspected that fumes are still present, the rescuer should wear an appropriate<br>mask or self-contained breathing apparatus. If not breathing, if breathing is irregular<br>or if respiratory arrest occurs, provide artificial respiration or oxygen by trained<br>personnel. It may be dangerous to the person providing aid to give mouth-to-mouth<br>resuscitation. Get medical attention. If necessary, call a poison center or physician.<br>If unconscious, place in recovery position and get medical attention immediately.<br>Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or<br>waistband.   |
| Skin contact               | : | Wash with plenty of soap and water. Remove contaminated clothing and shoes.<br>Wash contaminated clothing thoroughly with water before removing it, or wear<br>gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the<br>event of any complaints or symptoms, avoid further exposure. Wash clothing<br>before reuse. Clean shoes thoroughly before reuse.   |
| Ingestion                  | : | Wash out mouth with water. Remove dentures if any. Remove victim to fresh air<br>and keep at rest in a position comfortable for breathing. If material has been<br>swallowed and the exposed person is conscious, give small quantities of water to<br>drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not<br>induce vomiting unless directed to do so by medical personnel. If vomiting occurs,<br>the head should be kept low so that vomit does not enter the lungs. Get medical<br>attention. If necessary, call a poison center or physician. Never give anything by<br>mouth to an unconscious person. If unconscious, place in recovery position and get<br>medical attention immediately. Maintain an open airway. Loosen tight clothing such<br>as a collar, tie, belt or waistband. |
| Protection of first-aiders | : | No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.   |

#### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption

| Date of issue/Date of revision | : 1-11-2022  | Version : 1.02 |           |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue         | : 21-10-2022 | 4/19           | AkzoNobel |

## **SECTION 4: First aid measures**

through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate, Hydroxyphenyl-benzotriazole derivatives, Polymeric Benzotriazole. May produce an allergic reaction.

#### Over-exposure signs/symptoms

| Eye contact  | : No specific data.   |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness |
| Skin contact | : Adverse symptoms may include the following:<br>irritation<br>redness  |
| Ingestion    | : No specific data.   |

#### 4.3 Indication of any immediate medical attention and special treatment needed

| Notes to physician  | : Treat symptomatically. Contact poison treatment specialist immediately if large |
|---------------------|---|
|                     | quantities have been ingested or inhaled.   |
| Specific treatments | : No specific treatment.  |

## **SECTION 5: Firefighting measures**

| 5.1 Extinguishing media                           |                |   |   |   |
|---|----------------|---|---|---|
| Suitable extinguishing media                      | : เ            | Jse dry chemical, CO <sub>2</sub> , wa  | ter spray (fog) or foam.  |   |
| Unsuitable extinguishing media                    | : [            | Do not use water jet.   |   |   |
| 5.2 Special hazards arising f                     | from 1         | the substance or mixture  |   |   |
| Hazards from the substance or mixture             | li<br>ti<br>li | n a fire or if heated, a pres<br>he risk of a subsequent ex<br>asting effects. Fire water o | r. Runoff to sewer may create fire or<br>sure increase will occur and the cont<br>plosion. This material is harmful to a<br>contaminated with this material must<br>arged to any waterway, sewer or dra | ainer may burst, with<br>iquatic life with long<br>be contained and |
| Hazardous combustion products                     | c              | Decomposition products ma<br>carbon dioxide<br>carbon monoxide<br>netal oxide/oxides        | ay include the following materials:   |   |
| 5.3 Advice for firefighters                       |                |   |   |   |
| Special protective actions for fire-fighters      | t<br>s         | here is a fire. No action sh<br>suitable training. Move con                                 | by removing all persons from the vici<br>iall be taken involving any personal ri<br>tainers from fire area if this can be d<br>e-exposed containers cool.   | sk or without   |
| Special protective<br>equipment for fire-fighters | t<br>r<br>c    | preathing apparatus (SCBA<br>node. Clothing for fire-figh                                   | opropriate protective equipment and<br>) with a full face-piece operated in po-<br>ters (including helmets, protective bo-<br>andard EN 469 will provide a basic le                                     | ositive pressure<br>oots and gloves)                                |
| Date of issue/Date of revision                    |                | : 1-11-2022   | Version : 1.02  |   |
| Date of previous issue                            |                | : 21-10-2022  | 5/19  | AkzoNobel   |
|   |                |   |   |   |

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

| • • •                          |     |   |
|--------------------------------|-----|---|
| For non-emergency<br>personnel | :   | No action shall be taken involving any personal risk or without suitable training.<br>Evacuate surrounding areas. Keep unnecessary and unprotected personnel from<br>entering. Do not touch or walk through spilled material. Shut off all ignition sources.<br>No flares, smoking or flames in hazard area. Avoid breathing vapor or mist.<br>Provide adequate ventilation. Wear appropriate respirator when ventilation is<br>inadequate. Put on appropriate personal protective equipment. |
| For emergency responders       | :   | If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".   |
| 6.2 Environmental precautions  | :   | Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.  |
| 6.3 Methods and materials fo   | r c | ontainment and cleaning up  |
| Small spill                    | :   | Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble.<br>Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.   |
| Large spill                    | :   | Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-   |

combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.

# 6.4 Reference to other: See Section 1 for emergency contact information.sections: See Section 8 for information on appropriate personal protective equipment.<br/>See Section 13 for additional waste treatment information.

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

| Protective measures                       | history of skin sensitizati<br>which this product is use<br>Avoid breathing vapor of<br>adequate ventilation. W<br>Do not enter storage are<br>Keep in the original cont<br>material, kept tightly clos<br>open flame or any other<br>lighting and material har<br>precautionary measures | onal protective equipment (see Sec<br>on problems should not be employ<br>ed. Do not get in eyes or on skin of<br>mist. Avoid release to the enviror<br>ear appropriate respirator when ve<br>as and confined spaces unless ad<br>ainer or an approved alternative m<br>sed when not in use. Store and us<br>ignition source. Use explosion-pro-<br>idling) equipment. Use only non-sp<br>against electrostatic discharges.<br>be hazardous. Do not reuse cont | ved in any process in<br>r clothing. Do not ingest.<br>Inment. Use only with<br>entilation is inadequate.<br>lequately ventilated.<br>ade from a compatible<br>e away from heat, sparks,<br>pof electrical (ventilating,<br>parking tools. Take<br>Empty containers retain |
|---|---|--|--|
| Advice on general<br>occupational hygiene | handled, stored and pro-<br>eating, drinking and smo  | oking should be prohibited in areas<br>cessed. Workers should wash har<br>king. Remove contaminated cloth<br>ng eating areas. See also Section<br>neasures.  | nds and face before<br>ning and protective   |
| Date of issue/Date of revision            | : 1-11-2022   | <b>Version</b> : 1.02  |  |
| Date of previous issue                    | : 21-10-2022  | 6/19   | AkzoNobel  |

## **SECTION 7: Handling and storage**

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### Seveso Directive - Reporting thresholds

#### Danger criteria

| Categ | Notification and MAPP threshold | Safety report threshold |
|-------|---------------------------------|-------------------------|
| P5c   | 5000 tonne                      | 50000 tonne             |

#### 7.3 Specific end use(s)

| Recommendations            | : Not available |
|----------------------------|-----------------|
| Industrial sector specific | : Not available |

solutions

## **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

| Occupational exposure limits             |   |
|--|---|
| r butyl acetate                          | Institute of Occupational Health, Ministry of Social Affairs<br>(Finland, 12/2019).<br>STEL: 960 mg/m <sup>3</sup> 15 minutes.<br>STEL: 200 ppm 15 minutes.<br>TWA: 720 mg/m <sup>3</sup> 8 hours.<br>TWA: 150 ppm 8 hours.                       |
| 2-methoxy-1-methylethyl acetate          | Institute of Occupational Health, Ministry of Social Affairs<br>(Finland, 6/2018). Absorbed through skin.<br>TWA: 50 ppm 8 hours.<br>TWA: 270 mg/m <sup>3</sup> 8 hours.<br>STEL: 100 ppm 15 minutes.<br>STEL: 550 mg/m <sup>3</sup> 15 minutes.  |
| Reaction mass of ethylbenzene and xylene | Institute of Occupational Health, Ministry of Social Affairs<br>(Finland, 12/2019). Absorbed through skin.<br>STEL: 440 mg/m <sup>3</sup> 15 minutes.<br>STEL: 100 ppm 15 minutes.<br>TWA: 220 mg/m <sup>3</sup> 8 hours.<br>TWA: 50 ppm 8 hours. |
| 4-methylpentan-2-one                     | Institute of Occupational Health, Ministry of Social Affairs<br>(Finland, 12/2019).<br>STEL: 210 mg/m <sup>3</sup> 15 minutes.<br>STEL: 50 ppm 15 minutes.<br>TWA: 80 mg/m <sup>3</sup> 8 hours.<br>TWA: 20 ppm 8 hours.                          |



## **SECTION 8: Exposure controls/personal protection**

**Recommended monitoring procedures**If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

| Product/ingredient name           | Туре   | Exposure         | Value                  | Population | Effects   |
|-----------------------------------|--------|------------------|------------------------|------------|-----------|
| 2-ethoxy-1-methylethyl acetate    | DNEL   | Long term Oral   | 13.1 mg/               | General    | Systemic  |
|                                   |        |                  | kg bw/day              | population |           |
|                                   | DNEL   | Long term Dermal | 62 mg/kg               | General    | Systemic  |
|                                   |        | Ŭ                | bw/day                 | population | 5         |
|                                   | DNEL   | Long term Dermal | 103 mg/kg              | Workers    | Systemic  |
|                                   |        |                  | bw/day                 |            | - ,       |
|                                   | DNEL   | Long term        | 181 mg/m <sup>3</sup>  | General    | Systemic  |
|                                   | DINCL  | Inhalation       | 101 mg/m               | population | Oysternie |
|                                   | DNEL   | Long term        | 302 mg/m <sup>3</sup>  | Workers    | Systemic  |
|                                   | DINLL  | Inhalation       | 302 mg/m               | WUIKEIS    | Systemic  |
|                                   |        |                  | 265                    | Comoral    | Customia  |
|                                   | DNEL   | Short term       | 365 mg/m <sup>3</sup>  | General    | Systemic  |
|                                   |        | Inhalation       |                        | population |           |
|                                   | DNEL   | Short term       | 608 mg/m <sup>3</sup>  | Workers    | Systemic  |
|                                   |        | Inhalation       |                        |            |           |
| n-butyl acetate                   | DNEL   | Long term Oral   | 3.4 mg/kg              | General    | Systemic  |
|                                   |        |                  | bw/day                 | population |           |
|                                   | DNEL   | Long term Dermal | 3.4 mg/kg              | General    | Systemic  |
|                                   |        | -                | bw/day                 | population |           |
|                                   | DNEL   | Long term Dermal | 7 mg/kg                | Workers    | Systemic  |
|                                   |        | Ŭ                | bw/day                 |            | 5         |
|                                   | DNEL   | Long term        | 12 mg/m <sup>3</sup>   | General    | Systemic  |
|                                   |        | Inhalation       | ·= ···g, ···           | population |           |
|                                   | DNEL   | Long term        | 48 mg/m <sup>3</sup>   | Workers    | Systemic  |
|                                   | DINEL  | Inhalation       | 40 mg/m                | Workers    | Cysternie |
|                                   | DNEL   | Long term        | 102.34 mg/             | General    | Local     |
|                                   | DINEL  |                  | m <sup>3</sup>         |            | LUCAI     |
|                                   |        | Inhalation       |                        | population |           |
|                                   | DNEL   | Long term        | 480 mg/m <sup>3</sup>  | Workers    | Local     |
|                                   | DUE    | Inhalation       | 050 7 /                | <b>A</b>   |           |
|                                   | DNEL   | Short term       | 859.7 mg/              | General    | Local     |
|                                   |        | Inhalation       | m <sup>3</sup>         | population |           |
|                                   | DNEL   | Short term       | 859.7 mg/              | General    | Systemic  |
|                                   |        | Inhalation       | m³                     | population |           |
|                                   | DNEL   | Short term       | 960 mg/m³              | Workers    | Local     |
|                                   |        | Inhalation       |                        |            |           |
|                                   | DNEL   | Short term       | 960 mg/m <sup>3</sup>  | Workers    | Systemic  |
|                                   |        | Inhalation       |                        |            |           |
| Reaction mass of ethylbenzene and | DNEL   | Long term Oral   | 1.6 mg/kg              | General    | Systemic  |
| xylene                            |        |                  | bw/day                 | population |           |
| -                                 | DNEL   | Long term        | 14.8 mg/m <sup>3</sup> | General    | Systemic  |
|                                   |        | Inhalation       | <u> </u>               | population |           |
|                                   | DNEL   | Long term        | 77 mg/m³               | Workers    | Systemic  |
|                                   |        | Inhalation       |                        |            |           |
|                                   | DNEL   | Long term Dermal | 108 mg/kg              | General    | Systemic  |
|                                   |        | Long torm Derma  | bw/day                 | population |           |
|                                   | DNEL   | Long term Dermal | 180 mg/kg              | Workers    | Systemic  |
|                                   | DINEL  |                  | 100 mg/kg              | VUINCIS    | Cysternic |
|                                   |        |                  | <u> </u>               |            |           |
|                                   | -2022  |                  | Version                | :1.02      | Alizablah |
| e of previous issue : 21-1        | 0-2022 |                  | 8/19                   |            | AkzoNob   |

|                                     |       |  | bw/day                 |                                  |                      |
|-------------------------------------|-------|--|------------------------|----------------------------------|----------------------|
|                                     | DNEL  | Short term                             | 289 mg/m <sup>3</sup>  | Workers                          | Local                |
|                                     |       | Inhalation                             | g/                     |                                  |                      |
|                                     | DNEL  | Short term                             | 289 mg/m <sup>3</sup>  | Workers                          | Systemic             |
|                                     | DITLE | Inhalation                             | 200 mg/m               | Wontoro                          | Cyclonno             |
| 4-methylpentan-2-one                | DNEL  | Long term Oral                         | 4.2 mg/kg              | General                          | Systemic             |
|                                     | DINCL | Long term ora                          | bw/day                 | population                       | Gysternie            |
|                                     | DNEL  | Long term Dermal                       | 4.2 mg/kg              | General                          | Systemic             |
|                                     | DINLL | Long term Derma                        | bw/day                 |                                  | Systemic             |
|                                     |       | Long town Downol                       |                        | population                       | Curata mia           |
|                                     | DNEL  | Long term Dermal                       | 11.8 mg/               | Workers                          | Systemic             |
|                                     |       | 1                                      | kg bw/day              | 0                                | Lanal                |
|                                     | DNEL  | Long term                              | 14.7 mg/m <sup>3</sup> | General                          | Local                |
|                                     |       | Inhalation                             |                        | population                       |                      |
|                                     | DNEL  | Long term                              | 14.7 mg/m <sup>3</sup> | General                          | Systemic             |
|                                     |       | Inhalation                             |                        | population                       |                      |
|                                     | DNEL  | Long term                              | 83 mg/m³               | Workers                          | Local                |
|                                     |       | Inhalation                             |                        |                                  |                      |
|                                     | DNEL  | Long term                              | 83 mg/m³               | Workers                          | Systemic             |
|                                     |       | Inhalation                             |                        |                                  |                      |
|                                     | DNEL  | Short term                             | 155.2 mg/              | General                          | Local                |
|                                     |       | Inhalation                             | m³                     | population                       |                      |
|                                     | DNEL  | Short term                             | 155.2 mg/              | General                          | Systemic             |
|                                     |       | Inhalation                             | m <sup>3</sup>         | population                       |                      |
|                                     | DNEL  | Short term                             | 208 mg/m <sup>3</sup>  | Workers                          | Local                |
|                                     |       | Inhalation                             | <b>J</b>               |                                  |                      |
|                                     | DNEL  | Short term                             | 208 mg/m <sup>3</sup>  | Workers                          | Systemic             |
|                                     |       | Inhalation                             |                        |                                  | - ,                  |
| Hexanoic acid, 2-ethyl-, zinc salt, | DNEL  | Long term Oral                         | 0.83 mg/               | General                          | Systemic             |
| basic                               | DITLE | Long tonn ordi                         | kg bw/day              | population                       | Cyclonno             |
| 34510                               | DNEL  | Long term                              | $2.5 \text{ mg/m}^3$   | General                          | Systemic             |
|                                     | DINCE | Inhalation                             | 2.0 mg/m               | population                       | Gysterino            |
|                                     | DNEL  | Long term Dermal                       | 3.21 mg/               | General                          | Systemic             |
|                                     | DINLL | Long term Derma                        | kg bw/day              | population                       | Systemic             |
|                                     | DNEL  | Long term                              | 5 mg/m <sup>3</sup>    | Workers                          | Systemic             |
|                                     | DINEL |  | 5 mg/m                 | WUIKEIS                          | Systemic             |
|                                     |       | Inhalation                             | 0.44                   |                                  | Quanta and a         |
|                                     | DNEL  | Long term Dermal                       | 6.41 mg/               | Workers                          | Systemic             |
|                                     | DNE   |  | kg bw/day              |                                  |                      |
| propylidynetrimethanol              | DNEL  | Long term Oral                         | 1.68 mg/               | General                          | Systemic             |
|                                     |       |  | kg bw/day              | population                       |                      |
|                                     | DNEL  | Long term Dermal                       | 1.68 mg/               | General                          | Systemic             |
|                                     |       |  | kg bw/day              | population                       |                      |
|                                     | DNEL  | Long term Dermal                       | 2.79 mg/               | Workers                          | Systemic             |
|                                     |       |  | kg bw/day              | <b>.</b> .                       |                      |
|                                     | DNEL  | Long term                              | 5.03 mg/m <sup>3</sup> | General                          | Systemic             |
|                                     |       | Inhalation                             |                        | population                       |                      |
|                                     | DNEL  | Long term                              | 19.54 mg/              | Workers                          | Systemic             |
|                                     |       | Inhalation                             | m³                     |                                  |                      |
|                                     | DNEL  | Short term Oral                        | 50 mg/kg               | General                          | Systemic             |
|                                     |       |  | bw/day                 | population                       | -                    |
|                                     | DNEL  | Short term Dermal                      | 83.3 mg/               | General                          | Systemic             |
|                                     |       |  | kg bw/day              | population                       | ,                    |
|                                     | DNEL  | Short term Dermal                      | 138.8 mg/              | Workers                          | Systemic             |
|                                     |       | Bonnal                                 | kg bw/day              |                                  | -,                   |
|                                     | DITE  |  |                        |                                  | 1                    |
|                                     |       | Short term                             |                        | General                          | Systemic             |
|                                     | DNEL  | Short term                             | 925 mg/m <sup>3</sup>  | General                          | Systemic             |
|                                     |       | Short term<br>Inhalation<br>Short term |                        | General<br>population<br>Workers | Systemic<br>Systemic |

#### PNECs

No PNECs available.



## **SECTION 8: Exposure controls/personal protection**

| 8.2 Exposure controls            |   |
|----------------------------------|---|
| Appropriate engineering controls | : Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.   |
| Individual protection measu      | <u>es</u>   |
| Hygiene measures                 | : Wash hands, forearms and face thoroughly after handling chemical products,<br>before eating, smoking and using the lavatory and at the end of the working period.<br>Appropriate techniques should be used to remove potentially contaminated clothing.<br>Contaminated work clothing should not be allowed out of the workplace. Wash<br>contaminated clothing before reusing. Ensure that eyewash stations and safety<br>showers are close to the workstation location.   |
| Eye/face protection              | : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.   |
| Skin protection                  |   |
| Hand protection                  | : Chemical-resistant, impervious gloves complying with an approved standard should<br>be worn at all times when handling chemical products if a risk assessment indicates<br>this is necessary. Considering the parameters specified by the glove manufacturer,<br>check during use that the gloves are still retaining their protective properties. It<br>should be noted that the time to breakthrough for any glove material may be<br>different for different glove manufacturers. In the case of mixtures, consisting of<br>several substances, the protection time of the gloves cannot be accurately<br>estimated. |
|                                  | When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time >480 minutes according to EN374) is recommended. Recommended gloves: Viton ® or Nitrile, thickness $\geq$ 0.38 mm. When only brief contact is expected, a glove with protection class of 2 or higher (breakthrough time >30 minutes according to EN374) is recommended. Recommended gloves: Nitrile, thickness $\geq$ 0.12 mm. Gloves should be replaced regularly and if there is any sign of damage to the glove material.   |
|                                  | The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.   |
|                                  | The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.   |
| Body protection                  | : Personal protective equipment for the body should be selected based on the task<br>being performed and the risks involved and should be approved by a specialist<br>before handling this product. When there is a risk of ignition from static electricity,<br>wear anti-static protective clothing. For the greatest protection from static<br>discharges, clothing should include anti-static overalls, boots and gloves. Refer to<br>European Standard EN 1149 for further information on material and design<br>requirements and test methods.  |
| Other skin protection            | : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.   |
| Respiratory protection           | : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.  |



## **SECTION 8: Exposure controls/personal protection**

| Environmental exposure | : Emissions from ventilation or work process equipment should be checked to        |
|------------------------|--|
| controls               | ensure they comply with the requirements of environmental protection legislation.  |
|                        | In some cases, fume scrubbers, filters or engineering modifications to the process |
|                        | equipment will be necessary to reduce emissions to acceptable levels.              |

## **SECTION 9: Physical and chemical properties**

| 9.1 Information on basic physical               | and chemical properties   |
|---|---|
| <u>Appearance</u>                               |   |
| Physical state                                  | : Liquid.   |
| Color   | : Gray.   |
| Odor  | : Characteristic.   |
| Odor threshold                                  | : Not available.  |
| рН  | : Not available.  |
| Melting point/freezing point                    | : Not available.  |
| Initial boiling point and<br>boiling range      | : Not available.  |
| Flash point                                     | : Closed cup: 35°C  |
| Evaporation rate                                | : Not available.  |
| Flammability (solid, gas)                       | : Not available.  |
| Upper/lower flammability or<br>explosive limits | : Not available.  |
| Vapor pressure                                  | : Not available.  |
| Vapor density                                   | : Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 2.6 (Air = 1) |
| Density   | : 1.268 g/cm <sup>3</sup>   |
| Solubility(ies)                                 | : Insoluble in the following materials: cold water.   |
| Partition coefficient: n-octanol/<br>water      | : Not available.  |
| Auto-ignition temperature                       | : Not available.  |
| Decomposition temperature                       | : Not available.  |
| Viscosity                                       | : Kinematic (room temperature): 1.97 cm <sup>2</sup> /s<br>Kinematic (40°C): 1.01 cm <sup>2</sup> /s    |

## SECTION 10: Stability and reactivity

|  | -  |                            |  |  |  |
|--|--|----------------------------|--|--|--|
| 10.1 Reactivity                            | : No specific test data related to reactivity available for this p   | roduct or its ingredients. |  |  |  |
| 10.2 Chemical stability                    | : The product is stable.   |                            |  |  |  |
| 10.3 Possibility of<br>hazardous reactions | Under normal conditions of storage and use, hazardous reactions will not occur.  |                            |  |  |  |
| 10.4 Conditions to avoid                   | : Avoid all possible sources of ignition (spark or flame). Do braze, solder, drill, grind or expose containers to heat or so | •                          |  |  |  |
| 10.5 Incompatible materials                | : Reactive or incompatible with the following materials: oxidizing materials   |                            |  |  |  |
| 10.6 Hazardous<br>decomposition products   | : Under normal conditions of storage and use, hazardous de should not be produced.   | composition products       |  |  |  |
| Date of issue/Date of revision             | :1-11-2022 Version :1.02   |                            |  |  |  |
| Date of previous issue                     | : 21-10-2022 11/19   | AkzoNobel                  |  |  |  |

## **SECTION 11: Toxicological information**

#### **11.1 Information on toxicological effects**

#### Acute toxicity

| Product/ingredient name  | Result                | Species    | Dose                   | Exposure |
|--|-----------------------|------------|------------------------|----------|
| <mark>n-</mark> butyl acetate  | LC50 Inhalation Gas.  | Rat        | 390 ppm                | 4 hours  |
| -  | LC50 Inhalation Vapor | Mouse      | 6 g/m <sup>3</sup>     | 2 hours  |
|  | LD50 Dermal           | Rabbit     | >17600 mg/kg           | -        |
|  | LD50 Intraperitoneal  | Mouse      | 1230 mg/kg             | -        |
|  | LD50 Oral             | Guinea pig | 4700 mg/kg             | -        |
|  | LD50 Oral             | Mouse      | 6 g/kg                 | -        |
|  | LD50 Oral             | Rabbit     | 3200 mg/kg             | -        |
|  | LD50 Oral             | Rat        | 10768 mg/kg            | -        |
| Reaction mass of   | LC50 Inhalation Gas.  | Rat        | 5000 ppm               | 4 hours  |
| ethylbenzene and xylene  |                       |            |                        |          |
| 4-methylpentan-2-one   | LD50 Intraperitoneal  | Guinea pig | 800 mg/kg              | -        |
|  | LD50 Intraperitoneal  | Mouse      | 268 mg/kg              | -        |
|  | LD50 Intraperitoneal  | Rat        | 400 mg/kg              | -        |
|  | LD50 Oral             | Guinea pig | 1600 mg/kg             | -        |
|  | LD50 Oral             | Mouse      | 1900 mg/kg             | -        |
|  | LD50 Oral             | Mouse      | 2850 mg/kg             | -        |
|  | LD50 Oral             | Rat        | 2080 mg/kg             | -        |
|  | LD50 Oral             | Rat        | 4600 mg/kg             | -        |
| Hydrocarbons, C10-C13, n-<br>alkanes, isoalkanes, cyclics,<br>< 2% aromatics | LC50 Inhalation Vapor | Rat        | 8500 mg/m <sup>3</sup> | 4 hours  |
|  | LD50 Oral             | Rat        | >6 g/kg                | _        |
| propylidynetrimethanol   | LD50 Oral             | Mouse      | 13700 mg/kg            | -        |
|  | LD50 Oral             | Mouse      | 14000 mg/kg            | -        |
|  | LD50 Oral             | Rat        | 14100 mg/kg            | -        |
|  | LD50 Oral             | Rat        | 14000 mg/kg            | -        |

## Conclusion/Summary

: Not available.

:21-10-2022

#### Irritation/Corrosion

| Product/ingredient name                     | Result                   | Species | Score       | Exposure            | Observation |
|---|--------------------------|---------|-------------|---------------------|-------------|
| ┏-butyl acetate                             | Eyes - Moderate irritant | Rabbit  | -           | 100 mg              | -           |
|   | Skin - Moderate irritant | Rabbit  | -           | 24 hours 500        | -           |
|   |                          |         |             | mg                  |             |
| Reaction mass of<br>ethylbenzene and xylene | Eyes - Mild irritant     | Rabbit  | -           | 87 mg               | -           |
|   | Eyes - Severe irritant   | Rabbit  | -           | 24 hours 5          | -           |
|   | Skin - Mild irritant     | Rat     | _           | mg<br>8 hours 60 UI | _           |
|   | Skin - Moderate irritant | Rabbit  | -           | 24 hours 500        | -           |
|   |                          |         |             | mg                  |             |
|   | Skin - Moderate irritant | Rabbit  | -           | 100 %               | -           |
| 4-methylpentan-2-one                        | Eyes - Moderate irritant | Rabbit  | -           | 24 hours 100        | -           |
|   |                          |         |             | UI                  |             |
|   | Eyes - Severe irritant   | Rabbit  | -           | 40 mg               | -           |
|   | Skin - Mild irritant     | Rabbit  | -           | 24 hours 500<br>mg  | -           |
| Conclusion/Summary                          | : Not available.         |         |             |                     |             |
| -   | . Not available.         |         |             |                     |             |
| Sensitization                               |                          |         |             |                     |             |
| Conclusion/Summary                          | : Not available.         |         |             |                     |             |
| <u>Mutagenicity</u>                         |                          |         |             |                     |             |
| <b>Conclusion/Summary</b>                   | : Not available.         |         |             |                     |             |
| <b>Carcinogenicity</b>                      |                          |         |             |                     |             |
| Conclusion/Summary                          | : Not available.         |         |             |                     |             |
|   |                          |         |             |                     |             |
| Date of issue/Date of revision              | : 1-11-2022              | Vers    | sion : 1.02 |                     |             |



## **SECTION 11: Toxicological information**

#### Reproductive toxicity

**Conclusion/Summary** : Not available.

Teratogenicity

**Conclusion/Summary** : Not available.

Specific target organ toxicity (single exposure)

| Product/ingredient name                            | Category   | Route of exposure | Target organs   |
|--|--|-------------------|---|
| n-butyl acetate<br>2-methoxy-1-methylethyl acetate | Category 3<br>Category 3<br>Category 3<br>Category 3 | -<br>-<br>-       | Narcotic effects<br>Narcotic effects<br>Narcotic effects<br>Respiratory tract<br>irritation |
| 4-methylpentan-2-one                               | Category 3   | -                 | Narcotic effects  |

#### Specific target organ toxicity (repeated exposure)

| Product/ingredient name                  | Category   | Route of exposure | Target organs |
|--|------------|-------------------|---------------|
| Reaction mass of ethylbenzene and xylene | Category 2 | -                 | -             |

#### Aspiration hazard

| Product/ingredient name  | Result   |
|--|--|
| Reaction mass of ethylbenzene and xylene<br>Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, < 2%<br>aromatics | ASPIRATION HAZARD - Category 1<br>ASPIRATION HAZARD - Category 1 |

| Information on the likely | : Not available. |
|---------------------------|------------------|
| routes of exposure        |                  |

## Potential acute health effects

| known significant effects or critical hazards.   |   |
|--|---|
|  | siness or   |
| y cause an allergic skin reaction.               |   |
| n cause central nervous system (CNS) depression. |   |
| : Ca<br>diz<br>: Ma                              | <ul> <li>No known significant effects or critical hazards.</li> <li>Can cause central nervous system (CNS) depression. May cause drow dizziness.</li> <li>May cause an allergic skin reaction.</li> <li>Can cause central nervous system (CNS) depression.</li> </ul> |

#### Symptoms related to the physical, chemical and toxicological characteristics

| Eye contact  | : No specific data.   |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness |
| Skin contact | : Adverse symptoms may include the following:<br>irritation<br>redness  |
| Ingestion    | : No specific data.   |

#### Delayed and immediate effects and also chronic effects from short and long term exposure

| <u>Short term exposure</u>     |                  |                |           |
|--------------------------------|------------------|----------------|-----------|
| Potential immediate effects    | : Not available. |                |           |
| Potential delayed effects      | : Not available. |                |           |
| Date of issue/Date of revision | : 1-11-2022      | Version : 1.02 |           |
| Date of previous issue         | : 21-10-2022     | 13/19          | AkzoNobel |

## **SECTION 11: Toxicological information**

|                                | <u> </u>  |
|--------------------------------|---|
| Long term exposure             |   |
| Potential immediate<br>effects | Not available.  |
| Potential delayed effects      | Not available.  |
| Potential chronic health eff   | <u>ts</u>   |
| Not available.                 |   |
| Conclusion/Summary             | Not available.  |
| General                        | Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. |
| Carcinogenicity                | No known significant effects or critical hazards.   |
| Mutagenicity                   | No known significant effects or critical hazards.   |
| Reproductive toxicity          | No known significant effects or critical hazards.   |
| Other information              | Not available.  |

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

| Product/ingredient name | Result                                | Species                                   | Exposure |
|-------------------------|---------------------------------------|---|----------|
| -butyl acetate          | Acute LC50 32 mg/l Marine water       | Crustaceans - Artemia salina              | 48 hours |
|                         | Acute LC50 100000 µg/l Fresh water    | Fish - Lepomis macrochirus                | 96 hours |
|                         | Acute LC50 18000 µg/l Fresh water     | Fish - Pimephales promelas                | 96 hours |
|                         | Acute LC50 185000 µg/l Marine water   | Fish - Menidia beryllina                  | 96 hours |
|                         | Acute LC50 62000 µg/l Fresh water     | Fish - Danio rerio                        | 96 hours |
| Reaction mass of        | Acute LC50 13400 µg/l Fresh water     | Fish - Pimephales promelas                | 96 hours |
| ethylbenzene and xylene |                                       |   |          |
| 4-methylpentan-2-one    | Acute LC50 505000 µg/l Fresh water    | Fish - Pimephales promelas                | 96 hours |
| 2.1                     | Acute LC50 540000 µg/l Fresh water    | Fish - Pimephales promelas                | 96 hours |
|                         | Acute LC50 537000 µg/l Fresh water    | Fish - Pimephales promelas -              | 96 hours |
|                         |                                       | Juvenile (Fledgling, Hatchling, Weanling) |          |
|                         | Chronic NOEC 78 mg/l Fresh water      | Daphnia - Daphnia magna                   | 21 days  |
|                         | Chronic NOEC 168 mg/l Fresh water     | Fish - Pimephales promelas -<br>Embryo    | 33 days  |
| propylidynetrimethanol  | Acute EC50 13000000 µg/l Fresh water  |   | 48 hours |
|                         | Acute LC50 14400000 µg/l Marine water | Fish - Cyprinodon variegatus              | 96 hours |

Conclusion/Summary

: Not available.

#### 12.2 Persistence and degradability

**Conclusion/Summary** : Not available.

#### 12.3 Bioaccumulative potential



| SECTION 12: Ecological information |
|------------------------------------|
|------------------------------------|

| Product/ingredient name       | LogPow | BCF         | Potential |  |
|-------------------------------|--------|-------------|-----------|--|
| 2-ethoxy-1-methylethyl        | 0.76   | -           | low       |  |
| acetate                       |        |             |           |  |
| n-butyl acetate               | 2.3    | -           | low       |  |
| 2-methoxy-1-methylethyl       | 1.2    | -           | low       |  |
| acetate                       |        |             |           |  |
| Reaction mass of              | 3.12   | 8.1 to 25.9 | low       |  |
| ethylbenzene and xylene       |        |             |           |  |
| 4-methylpentan-2-one          | 1.9    | -           | low       |  |
| Hydrocarbons, C10-C13, n-     | -      | 10 to 2500  | high      |  |
| alkanes, isoalkanes, cyclics, |        |             | -         |  |
| < 2% aromatics                |        |             |           |  |
| Hexanoic acid, 2-ethyl-, zinc | -      | 60960       | high      |  |
| salt, basic                   |        |             | -         |  |
| propylidynetrimethanol        | -0.47  | <1          | low       |  |

#### 12.4 Mobility in soil

| Soil/water partition coefficient (Koc) | : Not available. |
|--|------------------|
| Mobility                               | : Not available. |

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Other adverse effects : No known significant effects or critical hazards.

## **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 13.1 Waste treatment methods

| <u>Product</u>          |  |
|-------------------------|--|
| Methods of disposal     | : The generation of waste should be avoided or minimized wherever possible.<br>Disposal of this product, solutions and any by-products should at all times comply<br>with the requirements of environmental protection and waste disposal legislation<br>and any regional local authority requirements. Dispose of surplus and non-<br>recyclable products via a licensed waste disposal contractor. Waste should not be<br>disposed of untreated to the sewer unless fully compliant with the requirements of<br>all authorities with jurisdiction. |
| Hazardous waste         | : The classification of the product may meet the criteria for a hazardous waste.   |
| Disposal considerations | : Do not allow to enter drains or watercourses.<br>Dispose of according to all federal, state and local applicable regulations.<br>If this product is mixed with other wastes, the original waste product code may no<br>longer apply and the appropriate code should be assigned.<br>For further information, contact your local waste authority.   |

#### European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

| Waste code                              |   | Waste designation   |          |
|---|---|---|----------|
| EWC 08 01 11*                           | waste paint and varnish containing organic solvents or other hazardous substances |   |          |
| <u>Packaging</u><br>Methods of disposal | packaging should be recy  | should be avoided or minimized who<br>cled. Incineration or landfill should |          |
|   | when recycling is not feas  | sidle.  |          |
| ate of issue/Date of revision           | : 1-11-2022   | Version : 1.02  | AkzoNobe |

## **SECTION 13: Disposal considerations**

| Disposal considerations | <ul> <li>Using information provided in this safety data sheet, advice should be obtained from<br/>the relevant waste authority on the classification of empty containers.<br/>Empty containers must be scrapped or reconditioned.<br/>Dispose of containers contaminated by the product in accordance with local or<br/>national legal provisions.</li> </ul>  |
|-------------------------|--|
| Special precautions     | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. |

## **SECTION 14: Transport information**

|                                    | ADR/RID | IMDG   | ΙΑΤΑ   |
|------------------------------------|---------|--------|--------|
| 14.1 UN number                     | UN1263  | UN1263 | UN1263 |
| 14.2 UN proper<br>shipping name    | PAINT   | PAINT  | PAINT  |
| 14.3 Transport<br>hazard class(es) | 3       | 3      | 3      |
| 14.4 Packing<br>group              | 111     | 111    |        |
| 14.5<br>Environmental<br>hazards   | No.     | No.    | No.    |

**Additional information** 

IMDG

| ADR/RID | : Tunnel code (D/E) |  |
|---------|---------------------|--|
|---------|---------------------|--|

| : | Emergency schedules F-E, | _S-E_ |
|---|--------------------------|-------|
|---|--------------------------|-------|

| 14.6 Special precautions for | : | Transport within user's premises: always transport in closed containers that are    |
|------------------------------|---|---|
| user                         |   | upright and secure. Ensure that persons transporting the product know what to do in |
|                              |   | the event of an accident or spillage.   |

| 14.7 Transport in bulk | : Not applicable. |
|------------------------|-------------------|
| according to IMO       |                   |
| instruments            |                   |

## **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

#### Annex XIV - List of substances subject to authorization

#### <u>Annex XIV</u>

None of the components are listed.

#### Substances of very high concern

None of the components are listed.



| SECTION 15: Regulatory information |  |
|------------------------------------|--|
|------------------------------------|--|

| Annex XVII - Restrictions<br>on the manufacture,<br>placing on the market<br>and use of certain<br>dangerous substances,<br>mixtures and articles   | : Not applicable.  |
|---|--|
| Other EU regulations  |  |
| VOC   | : The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information.   |
| VOC for Ready-for-Use<br>Mixture  | : Not applicable.  |
| Industrial emissions<br>(integrated pollution<br>prevention and control) -<br>Air   | : Not listed   |
| Industrial emissions<br>(integrated pollution<br>prevention and control) -<br>Water   | : Not listed   |
| Ozone depleting substance<br>Not listed.  | <u>es (1005/2009/EU)</u>   |
| Prior Informed Consent (P<br>Not listed.  | <u>IC) (649/2012/EU)</u>   |
| <u>Seveso Directive</u><br>This product is controlled un<br><u>Danger criteria</u>  | ider the Seveso Directive.   |
|   |  |
| Category  |  |
| Category<br>P5c   |  |
|   | : The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.   |
| P5c   | own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply  |
| P5c   | own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.  |
| P5c<br>Industrial use   | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations  | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations  | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations<br>Chemical Weapon Convent   | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations<br>Chemical Weapon Convent<br>Not listed.<br>Montreal Protocol<br>Not listed.  | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations<br>Chemical Weapon Convent<br>Not listed.<br>Montreal Protocol<br>Not listed.<br>Stockholm Convention on I<br>Not listed.                              | <ul> <li>own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.</li> <li>Not available.</li> <li>Not available.</li> </ul>  |
| P5c<br>Industrial use<br>NACE<br>UC62<br>International regulations<br>Chemical Weapon Convent<br>Not listed.<br>Montreal Protocol<br>Not listed.<br>Stockholm Convention on I<br>Not listed.<br>Rotterdam Convention on F | own assessment of workplace risks, as required by other health and safety<br>legislation. The provisions of the national health and safety at work regulations apply<br>to the use of this product at work.<br>Not available.<br>Not available.<br>ion List Schedules I, II & III Chemicals<br>Persistent Organic Pollutants<br>Prior Informed Consent (PIC) |

| Date of issue/Date of revision | : 1-11-2022 |
|--------------------------------|-------------|
| Date of previous issue         | :21-10-2022 |



## **SECTION 15: Regulatory information**

15.2 Chemical Safety Assessment

: No Chemical Safety Assessment has been carried out.

## **SECTION 16: Other information**

| Indicates information that h | nas changed from previously issued version. |  |
|------------------------------|---|--|
| Abbroviations and            | ATE - Acuto Toxicity Estimate               |  |

| acronyms       CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]         DMEL = Derived Minimal Effect Level       DNEL = Derived No Effect Level         DNEL = Derived No Effect Level       EUH statement = CLP-specific Hazard statement         N/A = Not available       PBT = Persistent, Bioaccumulative and Toxic         PNEC = Predicted No Effect Concentration       RRN = REACH Registration Number         SGG = Segregation Group       Very Bioaccumulative | Appreviations and | : ATE – Acule Toxicity Estimate                 |
|---|-------------------|---|
| DMEL = Derived Minimal Effect Level<br>DNEL = Derived No Effect Level<br>EUH statement = CLP-specific Hazard statement<br>N/A = Not available<br>PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group  | acronyms          |   |
| DNEL = Derived No Effect Level<br>EUH statement = CLP-specific Hazard statement<br>N/A = Not available<br>PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group   |                   | 1272/2008]                                      |
| EUH statement = CLP-specific Hazard statement<br>N/A = Not available<br>PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group   |                   | DMEL = Derived Minimal Effect Level             |
| N/A = Not available<br>PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group  |                   | DNEL = Derived No Effect Level                  |
| PBT = Persistent, Bioaccumulative and Toxic<br>PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group   |                   | EUH statement = CLP-specific Hazard statement   |
| PNEC = Predicted No Effect Concentration<br>RRN = REACH Registration Number<br>SGG = Segregation Group  |                   | N/A = Not available                             |
| RRN = REACH Registration Number<br>SGG = Segregation Group  |                   | PBT = Persistent, Bioaccumulative and Toxic     |
| SGG = Segregation Group   |                   | PNEC = Predicted No Effect Concentration        |
|   |                   | RRN = REACH Registration Number                 |
| VPVB - Very Persistent and Very Bioaccumulative   |                   | SGG = Segregation Group                         |
| VFVD – Very Fersistent and Very Dioaccumulative   |                   | vPvB = Very Persistent and Very Bioaccumulative |

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification          | Justification         |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226      | On basis of test data |
| Skin Sens. 1, H317      | Calculation method    |
| STOT SE 3, H336         | Calculation method    |
| Aquatic Chronic 3, H412 | Calculation method    |

#### Full text of abbreviated H statements

|                                 |                 |   | 1              |
|---------------------------------|-----------------|---|----------------|
| H225                            |                 | Highly flammable liquid and vapor.                    |                |
| H226                            |                 | Flammable liquid and vapor.                           |                |
| H304                            |                 | May be fatal if swallowed and enters airways.         |                |
| H312                            |                 | Harmful in contact with skin.                         |                |
| H315                            |                 | Causes skin irritation.                               |                |
| H317                            |                 | May cause an allergic skin reaction.                  |                |
| H319                            |                 | Causes serious eye irritation.                        |                |
| H332                            |                 | Harmful if inhaled.                                   |                |
| H335                            |                 | May cause respiratory irritation.                     |                |
| H336                            |                 | May cause drowsiness or dizziness.                    |                |
| H351                            |                 | Suspected of causing cancer.                          |                |
| H361                            |                 | Suspected of damaging fertility or the unborn         | child.         |
| H361d                           |                 | Suspected of damaging the unborn child.               |                |
| H361f                           |                 | Suspected of damaging fertility.                      |                |
| H373                            |                 | May cause damage to organs through prolong            | ed or repeated |
|                                 |                 | exposure.   |                |
| H400                            |                 | Very toxic to aquatic life.                           |                |
| H410                            |                 | Very toxic to aquatic life with long lasting effects. |                |
| H411                            |                 | Toxic to aquatic life with long lasting effects.      |                |
| H412                            |                 | Harmful to aquatic life with long lasting effects.    |                |
|                                 |                 | Repeated exposure may cause skin dryness or cracking. |                |
|                                 |                 |   |                |
| Full text of classifications [C | <u>[LP/GHS]</u> |   |                |
| Acute Tox. 4                    |                 | ACUTE TOXICITY - Category 4                           |                |
| Aquatic Acute 1                 |                 | AQUATIC HAZARD (ACUTE) - Category 1                   |                |
| Aquatic Chronic 1               |                 | AQUATIC HAZARD (LONG-TERM) - Categor                  | v 1            |
| Aquatic Chronic 2               |                 | AQUATIC HAZARD (LONG-TERM) - Categor                  |                |
| Aquatic Chronic 3               |                 | AQUATIC HAZARD (LONG-TERM) - Categor                  |                |
| Asp. Tox. 1                     |                 | ASPIRATION HAZARD - Category 1                        | , -            |
| Carc. 2                         |                 | CARCINOGENICITY - Category 2                          |                |
|                                 |                 | SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2       |                |
|                                 |                 | FLAMMABLE LIQUIDS - Category 2                        |                |
| Flam. Liq. 3                    |                 | FLAMMABLE LIQUIDS - Category 3                        |                |
| Repr. 2                         |                 | TOXIC TO REPRODUCTION - Category 2                    |                |
| Date of issue/Date of revision  | : 1-11-2022     | Version : 1.02  |                |
| Date of previous issue          | : 21-10-2022    | 18/19   | AkzoNobel      |
|                                 |                 |   |                |

| SECTION 16: Other information   |  |  |  |  |
|---------------------------------|--|--|--|--|
| Skin Irrit. 2                   | SKIN CORROSION/IRRITATION - Category 2             |  |  |  |
| Skin Sens. 1                    | SKIN SENSITIZATION - Category 1                    |  |  |  |
| Skin Sens. 1A                   | SKIN SENSITIZATION - Category 1A                   |  |  |  |
| STOT RE 2                       | SPECIFIC TARGET ORGAN TOXICITY (REPEATED           |  |  |  |
|                                 | EXPOSURE) - Category 2                             |  |  |  |
| STOT SE 3                       | SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) - |  |  |  |
|                                 | Category 3   |  |  |  |
| Date of printing                | : 1 November 2022                                  |  |  |  |
| Date of issue/ Date of revision | : 1 November 2022                                  |  |  |  |
| Date of previous issue          | : 21 October 2022                                  |  |  |  |
| Version                         | : 1.02   |  |  |  |
| Unique ID                       | :  |  |  |  |
|                                 |  |  |  |  |

#### Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

